Steven Cohen’s Protalix BioTherapeutics PLX Stock Holding History

Steven Cohen’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$59.6K	Buy	+25,566	New	+$54.1K	﹤0.01%	3770

Other funds holding PLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Steven Cohen's PLX Position: Q2 2026 in Review

Steven Cohen opened a new position in Protalix BioTherapeutics (PLX) in Q2 2026: 25,566 shares worth $59.6K. The stake represents ﹤0.01% of the portfolio and ranks #3770 among its holdings.

101 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

Steven Cohen held 25,566 shares of Protalix BioTherapeutics worth $59.6K as of Q2 2026.
Protalix BioTherapeutics was a new Steven Cohen position in Q2 2026.
Protalix BioTherapeutics made up ﹤0.01% of Steven Cohen's portfolio in Q2 2026, its #3770 holding.
101 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.